Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HIMS Stock Forecast 2026-2027
$29.76
Current Price
$6.78B
Market Cap
Buy 3
Hold 11
Sell 1
Wall St Analyst Ratings
Distance to HIMS Price Targets
+0.8%
To High Target of $30.00
-19.4%
To Median Target of $24.00
-46.2%
To Low Target of $16.00
HIMS Price Momentum
+22.5%
1 Week Change
+35.1%
1 Month Change
+17.4%
1 Year Change
-8.3%
Year-to-Date Change
-57.7%
From 52W High of $70.43
+116.6%
From 52W Low of $13.74
📊 TOP ANALYST CALLS
Did HIMS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Hims is one of their latest high-conviction picks.
Latest HIMS Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, HIMS has a neutral consensus with a median price target of $24.00 (ranging from $16.00 to $30.00). The overall analyst rating is Buy (6.4/10). Currently trading at $29.76, the median forecast implies a -19.4% downside. This outlook is supported by 3 Buy, 11 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Ryan MacDonald at Needham, projecting a 0.8% upside. Conversely, the most conservative target is provided by George Hill at Deutsche Bank, suggesting a 46.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HIMS Analyst Ratings
3
Buy
11
Hold
1
Sell
HIMS Price Target Range
Low
$16.00
Average
$24.00
High
$30.00
Current: $29.76
Latest HIMS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HIMS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 16, 2026 | B of A Securities | Allen Lutz | Neutral | Maintains | $25.00 |
| Mar 27, 2026 | TD Cowen | Jonna Kim | Hold | Maintains | $23.00 |
| Mar 16, 2026 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $25.00 |
| Mar 11, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $29.00 |
| Mar 10, 2026 | Deutsche Bank | George Hill | Hold | Maintains | $28.00 |
| Mar 10, 2026 | B of A Securities | Allen Lutz | Neutral | Upgrade | $23.00 |
| Mar 10, 2026 | Citigroup | Daniel Grosslight | Neutral | Upgrade | $24.00 |
| Mar 9, 2026 | Needham | Ryan MacDonald | Buy | Upgrade | $30.00 |
| Feb 25, 2026 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $21.00 |
| Feb 25, 2026 | Barclays | Glen Santangelo | Overweight | Maintains | $25.00 |
| Feb 24, 2026 | BTIG | David Larsen | Neutral | Downgrade | $N/A |
| Feb 24, 2026 | Citigroup | Daniel Grosslight | Sell | Maintains | $13.25 |
| Feb 24, 2026 | Leerink Partners | Michael Cherny | Market Perform | Maintains | $17.50 |
| Feb 24, 2026 | Truist Securities | Jailendra Singh | Hold | Reiterates | $18.00 |
| Feb 24, 2026 | TD Cowen | Jonna Kim | Hold | Maintains | $17.00 |
| Feb 24, 2026 | Evercore ISI Group | Mark Mahaney | In-Line | Maintains | $24.00 |
| Feb 9, 2026 | Citigroup | Daniel Grosslight | Sell | Maintains | $16.50 |
| Feb 9, 2026 | B of A Securities | Allen Lutz | Underperform | Maintains | $21.00 |
| Feb 9, 2026 | TD Cowen | Jonna Kim | Hold | Maintains | $20.00 |
| Feb 2, 2026 | BTIG | David Larsen | Buy | Maintains | $60.00 |
Hims & Hers Health, Inc. (HIMS) Competitors
The following stocks are similar to Hims based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Hims & Hers Health, Inc. (HIMS) Financial Data
Hims & Hers Health, Inc. has a market capitalization of $6.78B with a P/E ratio of 60.7x. The company generates $2.35B in trailing twelve-month revenue with a 5.5% profit margin.
Revenue growth is +28.4% quarter-over-quarter, while maintaining an operating margin of +2.7% and return on equity of +25.2%.
Valuation Metrics
Market Cap
$6.78B
Enterprise Value
$7.33B
P/E Ratio
60.7x
PEG Ratio
-2.4x
Price/Sales
2.9x
Growth & Margins
Revenue Growth (YoY)
+28.4%
Gross Margin
+71.9%
Operating Margin
+2.7%
Net Margin
+5.5%
EPS Growth
-20.8%
Financial Health
Cash/Price Ratio
+8.5%
Current Ratio
1.9x
Debt/Equity
207.2x
ROE
+25.2%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Hims & Hers Health, Inc. (HIMS) Business Model
About Hims & Hers Health, Inc.
What They Do
Telehealth platform providing personalized medical care.
Business Model
The company operates a direct-to-consumer model, monetizing through consultations, prescription medications, and a range of wellness products. By connecting consumers with licensed healthcare professionals, it offers a secure online intake process and ongoing clinical support, allowing for diverse revenue streams across multiple health specialties.
Additional Information
Hims & Hers Health, Inc. was founded in 2017 and is headquartered in San Francisco, California. It serves customers across all 50 U.S. states and internationally in several countries, emphasizing clinical quality, customer privacy, and accessibility to empower users in managing their health challenges.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,442
CEO
Mr. Andrew Dudum
Country
United States
IPO Year
2021
Website
www.hims.comHims & Hers Health, Inc. (HIMS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
Hims & Hers Health, Inc. (HIMS) reached $29.76 at the closing of the latest trading day, reflecting a -4.03% change compared to its last close.
Apr 21, 2026
By Zacks Equity Research
Tale of the Tape
Hims & Hers Builds Scalable Data-Driven Personalized Care Platform
HIMS is building a data-driven care platform, adding Labs and multi-cancer testing to personalize treatment via continuous monitoring insights.
Apr 21, 2026
By Debanjana Dey
Analyst Blog
Danaher Gears Up to Post Q1 Earnings: What Lies Ahead for the Stock?
DHR heads into Q1 results with rising bioprocessing demand and steady estimates, but cost pressures and FX headwinds could weigh on performance.
Apr 16, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Hims & Hers Health (NYSE:HIMS) shares rose 9% in early trading, increasing from $28.82 to over $31 ahead of its earnings report scheduled for May 11.
Why It Matters
The 9% surge in Hims & Hers shares indicates strong investor confidence and speculation ahead of the earnings report, suggesting potential positive financial results or guidance.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
HIMS is developing a data-driven care platform that includes Labs and multi-cancer testing, aimed at personalizing treatment through continuous monitoring insights.
Why It Matters
HIMS' development of a data-driven care platform and multi-cancer testing indicates potential for innovation in personalized medicine, which could enhance revenue and market position.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Hims & Hers Health, Inc. (HIMS) Declines More Than Market: Some Information for Investors
18 hours ago
Quick Summary
Hims & Hers Health, Inc. (HIMS) closed at $29.76, down 4.03% from the previous trading day.
Why It Matters
The decline in Hims & Hers Health's stock price signals potential concerns about its market performance or investor sentiment, affecting future investment decisions.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
The GLP-1 weight-loss market has emerged as a multi-billion-dollar opportunity, combining medication access with continuous patient support.
Why It Matters
The surge in the GLP-1 weight-loss market indicates strong revenue potential, attracting investment and signaling growth in healthcare and pharmaceuticals.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program
19 hours ago
Quick Summary
Hims & Hers Health (NYSE: HIMS) closed at $29.76, down 4.03%, following Amazon's launch of a competing weight-loss program. Market cap is $7.1B, with a 52-week range of $13.74 - $70.43.
Why It Matters
Hims & Hers Health's stock drop reflects competitive pressures from Amazon's new weight-loss program, impacting market sentiment despite recent gains. This could affect future growth and profitability.
Source: The Motley Fool
Market Sentiment:
Neutral
What's Going On With Hims & Hers Shares
5 days ago
Quick Summary
The FDA plans to hold a meeting in July to discuss easing regulations on peptide injections, which are gaining popularity among fitness influencers and celebrities.
Why It Matters
Loosening regulations on peptide injections could boost the market for these treatments, benefiting related biotech and pharmaceutical companies and potentially driving stock prices higher.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About HIMS Stock
What is Hims & Hers Health, Inc.'s (HIMS) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, Hims & Hers Health, Inc. (HIMS) has a median price target of $24.00. The highest price target is $30.00 and the lowest is $16.00.
Is HIMS stock a good investment in 2026?
According to current analyst ratings, HIMS has 3 Buy ratings, 11 Hold ratings, and 1 Sell ratings. The stock is currently trading at $29.76. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HIMS stock?
Wall Street analysts predict HIMS stock could reach $24.00 in the next 12 months. This represents a -19.4% decrease from the current price of $29.76. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Hims & Hers Health, Inc.'s business model?
The company operates a direct-to-consumer model, monetizing through consultations, prescription medications, and a range of wellness products. By connecting consumers with licensed healthcare professionals, it offers a secure online intake process and ongoing clinical support, allowing for diverse revenue streams across multiple health specialties.
What is the highest forecasted price for HIMS Hims & Hers Health, Inc.?
The highest price target for HIMS is $30.00 from Ryan MacDonald at Needham, which represents a 0.8% increase from the current price of $29.76.
What is the lowest forecasted price for HIMS Hims & Hers Health, Inc.?
The lowest price target for HIMS is $16.00 from George Hill at Deutsche Bank, which represents a -46.2% decrease from the current price of $29.76.
What is the overall HIMS consensus from analysts for Hims & Hers Health, Inc.?
The overall analyst consensus for HIMS is neutral. Out of 22 Wall Street analysts, 3 rate it as Buy, 11 as Hold, and 1 as Sell, with a median price target of $24.00.
How accurate are HIMS stock price projections?
Stock price projections, including those for Hims & Hers Health, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 9:44 AM UTC